Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 5:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Daily placebo Clear all
Terminated Phase 4 Interventional Results available

Sodium Supplementation and Growth in Very Low Birth Weight Infants

NCT01795638
View directory record Official record
Conditions
Extreme Immaturity
Interventions
Sodium chloride, Placebo
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
7 Days to 8 Days
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 6, 2020 · Synced Sep 26, 2026, 5:05 PM EDT
Terminated Phase 3 Interventional Results available

Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery

NCT01011478
View directory record Official record
Conditions
Colorectal Cancer, Precancerous Condition
Interventions
rosuvastatin, placebo
Drug · Other
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
584
States / cities
Anniston, Alabama • Mobile, Alabama • Fort Smith, Arkansas + 423 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2023 · Synced Sep 26, 2026, 5:05 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Complementary and Alternative Medicine for Urological Symptoms(CAMUS)

NCT00603304
View directory record Official record
Conditions
Urological
Interventions
Saw Palmetto - first 24 weeks, Placebo - first 24 weeks, Saw Palmetto - weeks 24 - 48, Placebo - weeks 24 - 48, Saw Palmetto - weeks 48 - 72, Placebo - weeks 48 - 72
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
45 Years and older · Male only
Enrollment
369 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
10
States / cities
Oakland, California • Aurora, Colorado • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2012 · Synced Sep 26, 2026, 5:05 PM EDT
Completed Phase 3 Interventional

Feasibility Study of PH94B Nasal Spray for Acute Treatment of Social Anxiety Disorder (SAD)

NCT02622958
View directory record Official record
Conditions
Social Anxiety Disorder
Interventions
PH94B, Placebo
Drug · Other
Lead sponsor
Pherin Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 6, 2015 · Synced Sep 26, 2026, 5:05 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Naltrexone and Hypoglycemia in Type 1 Diabetes

NCT01053078
View directory record Official record
Conditions
Type 1 Diabetes, Hypoglycemia Unawareness
Interventions
Naltrexone, Placebo
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Sep 26, 2026, 5:05 PM EDT
Recruiting Phase 3 Interventional

Novel Strategies for Reducing Burn Scar Itch

NCT06801626
View directory record Official record
Conditions
Burn Scar, Itch Scarring, Wound
Interventions
Famotidine and 4% topical cromolyn sodium, Placebo
Combination Product · Other
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 80 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Sep 26, 2026, 5:05 PM EDT
Terminated Phase 1 Interventional

Probiotic LGG for Prevention of Side Effects in Patients Undergoing Chemoradiation for Gastrointestinal Cancer

NCT01790035
View directory record Official record
Conditions
Gastrointestinal Neoplasms
Interventions
LGG, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Sep 26, 2026, 5:05 PM EDT
Terminated Phase 4 Interventional Results available

Using Sitagliptin as a Treatment to Prevent New Onset Diabetes After Kidney Transplantation

NCT00936663
View directory record Official record
Conditions
Type 2 Diabetes, End Stage Renal Disease
Interventions
Placebo, Sitagliptin
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 70 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 12, 2023 · Synced Sep 26, 2026, 5:05 PM EDT
Completed Phase 4 Interventional Results available

PORtopulmonary Hypertension Treatment wIth maCitentan - a randOmized Clinical Trial

NCT02382016
View directory record Official record
Conditions
Portopulmonary Hypertension
Interventions
Macitentan, Placebo
Drug · Other
Lead sponsor
Actelion
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
29
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Sep 26, 2026, 5:05 PM EDT
Completed Phase 3 Interventional Results available

Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI)

NCT01442038
View directory record Official record
Conditions
Coronary Artery Disease, Angina Pectoris
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
2,651 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
86
States / cities
Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Sep 26, 2026, 5:05 PM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy, Safety and Tolerability of DFV890 in Patients With Knee Osteoarthritis

NCT04886258
View directory record Official record
Conditions
Symptomatic Knee Osteoarthritis
Interventions
DFV890, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years to 80 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
7
States / cities
Phoenix, Arizona • El Cajon, California • Colorado Springs, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Sep 26, 2026, 5:05 PM EDT
Completed Phase 3 Interventional Results available

Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®

NCT01696058
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium, Placebo matching Olodaterol, Olodaterol
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
1,137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
94
States / cities
Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 82 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2014 · Synced Sep 26, 2026, 5:05 PM EDT
Completed Phase 3 Interventional

Liprotamase Efficacy Trial in Patients With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency

NCT00449878
View directory record Official record
Conditions
Cystic Fibrosis, Exocrine Pancreatic Insufficiency
Interventions
Liprotamase, Placebo
Drug
Lead sponsor
Anthera Pharmaceuticals
Industry
Eligibility
7 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
29
States / cities
Los Angeles, California • Stanford, California • Denver, Colorado + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2014 · Synced Sep 26, 2026, 5:05 PM EDT
Completed Early Phase 1 Interventional

Improving Walking Automaticity in Parkinson's Disease: Levodopa or Donepezil

NCT03599726
View directory record Official record
Conditions
Parkinson Disease
Interventions
Donepezil, Placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
50 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 10, 2020 · Synced Sep 26, 2026, 5:05 PM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Sleep and Inflammatory Resolution Pathway

NCT03377543
View directory record Official record
Conditions
Inflammatory Response, Inflammation, Sleep, Sleep Restriction
Interventions
Aspirin, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 23, 2025 · Synced Sep 26, 2026, 5:05 PM EDT
Terminated Phase 3 Interventional Results available

Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 3)

NCT03400943
View directory record Official record
Conditions
Uterine Fibroids
Interventions
Vilaprisan (BAY1002670), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Female only
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
52
States / cities
Birmingham, Alabama • Arcadia, California • Cerritos, California + 43 more
Source: ClinicalTrials.gov public record
Updated May 2, 2023 · Synced Sep 26, 2026, 5:05 PM EDT
Terminated Not applicable Interventional Results available

Metabolic Effects of Hydroxychloroquine

NCT02026232
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Hydroxychloroquine, Hydroxychloroquine Placebo
Drug · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 27, 2023 · Synced Sep 26, 2026, 5:05 PM EDT
Completed Phase 3 Interventional Results available

Study of the Effectiveness of Three Different Doses of OPC-34712 in the Treatment of Adults With Acute Schizophrenia

NCT01396421
View directory record Official record
Conditions
Acute Schizophrenia
Interventions
OPC-34712 [Brexpiprazole] High Dose, Experimental: OPC-34712 [Brexpiprazole] Middle Dose, Experimental: OPC-34712 [Brexpiprazole] Low Dose, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
636 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
17
States / cities
Little Rock, Arkansas • Garden Grove, California • Glendale, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2015 · Synced Sep 26, 2026, 5:05 PM EDT
Active, not recruiting Phase 2 Interventional

The Role of Estrogen in the Neurobiology of Eating Disorders

NCT03740204
View directory record Official record
Conditions
Eating Disorders, Hypoestrogenemia
Interventions
17-β estradiol transdermal patches with cyclic progesterone, Placebo patch and pill
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
14 Years to 35 Years · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 26, 2026, 5:05 PM EDT
Completed Phase 3 Interventional Results available

Fesoterodine Flexible Dose Study

NCT00536484
View directory record Official record
Conditions
Overactive Bladder
Interventions
Fesoterodine, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
896 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
95
States / cities
Mobile, Alabama • Chandler, Arizona • Peoria, Arizona + 81 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2009 · Synced Sep 26, 2026, 5:05 PM EDT
Completed Phase 3 Interventional Results available

Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)

NCT01974752
View directory record Official record
Conditions
Metastatic, Uveal Melanoma
Interventions
75mg selumetinib, placebo, Dacarbazine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
7
States / cities
Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2017 · Synced Sep 26, 2026, 5:05 PM EDT
Terminated Phase 2 Interventional Results available

Phase IIa L-serine Trial for eAD

NCT03062449
View directory record Official record
Conditions
Alzheimer Disease
Interventions
L-Serine, Placebo Gummy
Drug · Other
Lead sponsor
Aleksandra Stark
Other
Eligibility
Not listed
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced Sep 26, 2026, 5:05 PM EDT
Terminated Not applicable Interventional Results available

Open-label Study of the Efficacy of Intranasal Oxytocin in Schizophrenia

NCT02144155
View directory record Official record
Conditions
Schizophrenia
Interventions
Oxytocin: 24IU - 168 IU, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 8, 2019 · Synced Sep 26, 2026, 5:05 PM EDT
Completed Phase 4 Interventional Results available

A Study of Suvorexant in Patients With Multiple Sclerosis Fatigue and Insomnia

NCT03110315
View directory record Official record
Conditions
Multiple Sclerosis, Fatigue, Insomnia
Interventions
Suvorexant, Placebo
Drug
Lead sponsor
Theodore R. Brown, MD MPH
Other
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Kirkland, Washington
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Sep 26, 2026, 5:05 PM EDT